SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma.

Biosci Rep · 2022 · PMC8753343 · PMID 34984436

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In both OS (70.5 versus 63.4% on 5-year OS rate, P =0.31) and PFS groups (71.4 versus 47.3% on 5-year PFS rate, P =0.074), the data showed a trend, although not statistically significant, towards worse clinical outcomes in patients with weak SMARCB1 gene expression ( Figure 5 C,D).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.